Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss.
The need-to-know this morning
Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting that the drug led to significant weight loss in a mid-stage trial.
Intellia Therapeutics said the FDA lifted a clinical hold on a Phase 3 study of its CRISPR gene-editing therapy for a condition called transthyretin amyloidosis, or ATTR, that mostly affects nerves. A clinical hold on a separate Phase 3 study of the therapy in ATTR that affects the heart remains in place.
New startup to develop a GLP-1 drug for addiction
A company called Baseline Therapeutics launched today with a focus on studying a GLP-1 drug for various substance use disorders.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.